Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at World Microbe Forum

WALTHAM, Mass., June 18, 2021 (GLOBE NEWSWIRE) —

Entasis Therapeutics

Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the World Microbe Forum 2021, taking place virtually June 20-24. Entasis will present 11 posters with one oral presentation highlighting ETX0462, a novel, first-in-class, diazabicyclooctane with antimicrobial activity against

Pseudomonas aeruginosa.

Presentations will also include updates on SUL-DUR, a β-lactam/β-lactamase inhibitor currently in a Phase 3 registrational clinical trial to treat infections caused by carbapenem-resistant

Acinetobacter baumannii

, and ETX0282CPDP, an oral β-lactam/β-lactamase inhibitor being developed to treat multidrug-resistant Gram-negative pathogens, including those caused by extended-spectrum β-lactamases (ESBLs) and carbapenem-resistant

Enterobacteriaceae

(CRE).

The details of the presentations are as follows:

SUL-DUR Presentations:

Poster

: Outer membrane permeability and efflux do not limit antibacterial activity of sulbactam-durlobactam in

Acinetobacter baumannii



Session:

AAR09 Pharmacological Studies of Investigational Agents Pre-NDA


Poster Number: WMF21-0322

Poster

: Effect of Susceptibility Testing Conditions on the

In Vitro

Antibacterial Activity of Sulbactam-Durlobactam


Session

: AAR09 Pharmacological Studies of Investigational Agents Pre-NDA


Poster Number: WMF21-0325

Poster

: Sulbactam-Durlobactam MIC and Disk Diffusion Quality Control Ranges Using a CLSI M23-A4 Study Design


Session

: AAR09 Pharmacological Studies of Investigational Agents Pre-NDA


Poster Number: WMF21-0326

ETX0282CPDP Presentation:

Poster

: The β-lactamase inhibitor ETX1317 restores the activity of cefpodoxime against recent (2017-2019), geographically diverse drug-resistant

Enterobacterales

isolates


Session

: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)


Poster Number: WMF21-0290

ETX0462 Presentations:

Oral Presentation

: The Discovery of the Novel Diazabicyclooctane (DBO) ETX0462: A Single Antibacterial Agent to Treat Gram-negative Infections, Including MDR

Pseudomonas aeruginosa



Session

: AAR107 New Agents Discovery Summary Session: Early New Antimicrobial Agents


Date and Time

: Monday, June 21, 2021, 11:00am-12:30 pm

Poster

: ETX0462 Inhibits Penicillin-Binding Protein 3 of

Pseudomonas aeruginosa

and

Escherichia coli



Session

: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)


Poster Number

: WMF21-0287

Poster

: ETX0462 is a Novel PBP Inhibitor with Potent Activity against Recent, Global, Gram-Negative, Clinical Isolates


Session

: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)


Poster Number

: WMF21-0293

Poster

: The Novel, Non-β-lactam PBP Inhibitor, ETX0462, Retains Potent Antibacterial Activity Across Isogenic Panels of Gram-negative Resistant Determinants


Session

: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)


Poster Number

: WMF21-0288

Poster

: ETX0462, a Novel Non β-lactam PBP Inhibitor, Is Bactericidal Against Gram negative pathogens with a Low Propensity for Mutant Generation


Session

: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)


Poster Number

: WMF21-0286

Poster

: Evaluation of the Pharmacokinetics/Pharmacodynamics (PK/PD) of the Novel Diazabicyclooctane (DBO) ETX0462 Against

Pseudomonas aeruginosa

Infections, Including MDR Strains


Session

: AAR07 Antimicrobial Pharmacokinetics and Pharmacodynamics


Poster Number

: WMF21-0292

Poster

: The Novel, Non-β-lactam PBP Inhibitor, ETX0462, Has Potent Activity Against Biothreat Pathogens

In Vitro

and

In Vivo



Session

: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)


Date and Time

: WMF21-0312

About Entasis Therapeutics Inc.


Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting

Acinetobacter baumannii

infections), zoliflodacin (targeting

Neisseria gonorrhoeae

infections), ETX0282CPDP (targeting

Enterobacteriaceae

infections) and ETX0462 (targeting

Pseudomonas

infections). For more information, visit www.entasistx.com.